

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT7584951

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	ROBERT F. BARGATZE	08/28/2020
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	TAKEDA VACCINES, INC.	
<b>Street Address:</b>	75 SIDNEY STREET	
<b>City:</b>	CAMBRIDGE	
<b>State/Country:</b>	MASSACHUSETTS	
<b>Postal Code:</b>	02139	
<b>PROPERTY NUMBERS Total: 2</b>		
<b>Property Type</b>	<b>Number</b>	
<b>Application Number:</b>	15836030	
<b>Application Number:</b>	16894291	
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>	(202)842-7899	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	6179372300	
<b>Email:</b>	jvecchia@cooley.com, zIPPatentDocketingMailboxUS@cooley.com	
<b>Correspondent Name:</b>	COOLEY LLP, ATTN: PATENT GROUP	
<b>Address Line 1:</b>	1299 PENNSYLVANIA AVENUE, NW	
<b>Address Line 2:</b>	SUITE 700	
<b>Address Line 4:</b>	WASHINGTON, D.C. 20004	
<b>ATTORNEY DOCKET NUMBER:</b>	LIGO-024/03US; -024/04US	
<b>NAME OF SUBMITTER:</b>	ALEXIA S. DILG	
<b>SIGNATURE:</b>	/Alexia S. Dilg/	
<b>DATE SIGNED:</b>	10/11/2022	
<b>Total Attachments: 5</b>		
source=LIGO-024_03US and LIGO-024_04US Assignment (Bargatze to Takeda) FULLY-EXECUTED#page1.tif		
source=LIGO-024_03US and LIGO-024_04US Assignment (Bargatze to Takeda) FULLY-EXECUTED#page2.tif		
source=LIGO-024_03US and LIGO-024_04US Assignment (Bargatze to Takeda) FULLY-EXECUTED#page3.tif		
source=LIGO-024_03US and LIGO-024_04US Assignment (Bargatze to Takeda) FULLY-EXECUTED#page4.tif		



Attorney Docket No. LIGO-024/03US 306927-2364  
Attorney Docket No. LIGO-024/04US 306927-2438

### ASSIGNMENT

Robert F. Bargatze, with a mailing address of 84 Vandolah Rd, Three Forks, MT 59752, (referred to as "Assignor") has made an invention(s) (the "Invention(s)") set forth in an application for patent, entitled **PARENTERAL NOROVIRUS VACCINE FORMULATIONS**, and which is a:

- (1) ☒ Non-provisional application
  - (a) ☐ to be filed herewith; or
  - (b) ☒ bearing Application No. 15/836,030, and filed on December 8, 2017;
- (2) ☒ non-provisional application
  - (a) ☐ to be filed herewith; or
  - (b) ☒ bearing Application No. 16/894,291, and filed on June 5, 2020;  
and/or
- (3) ☐ PCT application
  - (a) ☐ bearing Application No. , and filed on .  
  
and/or
- (4) ☐ attached hereto.

WHEREAS, Takeda Vaccines, Inc., mailing address of 75 Sidney Street, Cambridge, MA 02139, its successors, legal representatives, and assigns (the "Assignee"), is desirous of acquiring the entire right, title, and interest in: the Invention(s); the application(s) for patent identified above; the right to file applications for patent of the United States or other countries on the Invention(s); any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, these applications; any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of these application(s); and any and all patent(s) of the United States or other countries that may be granted therefor or thereon.

NOW, THEREFORE, for good and sufficient consideration, the receipt of which is hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of said prior agreement, the Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set

over, unto the Assignee, its successors, legal representatives, and assigns, the Assignor's entire right, title, and interest in:

- (a) the Invention(s);
- (b) the application(s) for patent identified above;
- (c) the right to file applications for patent of the United States or other countries on the Invention(s), including all rights under the Hague Convention, the Paris Convention for the Protection of Industrial Property, and under the Patent Cooperation Treaty, and all rights of claiming priority in any country of the world;
- (d) any application(s) for patent of the United States or other countries claiming the Invention(s);
- (e) any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, at least one of the application(s) for patent identified above or any application(s) for patent claiming the Invention(s), including any priority application(s), substitute application(s), division(s), continuation(s), and continuation(s)-in-part;
- (f) any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of any application for patent identified in the preceding paragraphs (b)-(e) and of any and all patent(s) granted based thereon in the United States and in all other countries; and
- (g) any patent(s) of the United States or other countries that may be granted for or on any application for patent identified in the preceding paragraphs (b)-(e), including any reissue(s), reexamination(s), revival(s), renewal(s) and extension(s) of said patent(s).

The above-granted rights, titles, and interests are to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made.

The Assignor hereby represents to the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, or if applicable, at such time said prior agreement was executed, the Assignor is the sole and lawful owner of the entire right, title, and interest in and to the Invention(s), that the Invention(s) are unencumbered, except, if applicable, by obligation to assign in accordance with said prior agreement, and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth herein, and that Assignor will not make or enter into any assignment, sale, agreement or encumbrance which would conflict with these presents.

Attorney Docket No. LIGO-024/03US 306927-2364  
Attorney Docket No. LIGO-024/04US 306927-2438

The Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that the Assignor will sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done in connection with any and all proceedings for the procurement, maintenance, enforcement and defense of the Invention(s), said application(s), and said patent(s), including interference and derivation proceedings, and any post-grant proceedings (e.g., opposition proceedings, post-grant reviews, Inter partes reviews, supplemental examinations, etc.), without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignor, its successors, legal representatives, and assigns.

The Assignor hereby requests the Commissioner of Patents to issue said patents of the United States to the Assignee for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

Attorney Docket No. LIGO-024/03US 306927-2364  
Attorney Docket No. LIGO-024/04US 306927-2438

August 28<sup>th</sup> 2020  
Date

Robert F. Bargatze  
Robert F. Bargatze

Witness:

August 28, 2020  
Date  
  
Date


Jung M. Kim

Attorney Docket No. LIGO-024/03US 306927-2364  
Attorney Docket No. LIGO-024/04US 306927-2438


For and on behalf of ASSIGNEE:

Date: Nov. 30, 2020

By:

  
Name: O. Oliver Mechnich  
Title: IP Therapeutic Area Head, Vaccines  
Company: Takeda Vaccines, Inc.


Witness:

  
Signature

30.11.2020  
Date

Bianca Boech  
Printed name

Witness:

  
Signature

30.11.2020  
Date

OLAF WROBEL  
Printed name